New York, February 27^th, 2020: SWORD Health (SWORD), a tech-enabled provider of musculoskeletal care, today announced the addition of $9 million to their Series A investment, bringing their total Series A investment to $17 million.

Munich, January 20th, 2020 – Prosthetic feet from the 3D printer are no longer an utopia, but reality. The combination of designing a foot in the computer and fast production through 3D printing creates a completely new ability to act, as Mercuris GmbH proves.

Gosselies, Belgium – February 14^th, 2020 – OncoDNA ("OncoDNA or "the Company"), the healthcare technology company making precision medicine a reality, today announced that it has completed a €19 million ($20 million) Series B equity financing.

Munich, Germany / February 10^th, 2020. – Successful Munich-based medical technology company Mecuris will be led by a new CEO, Peter Fröhlingsdorf (50), a renowned industry expert. Since the beginning of January this year, Fröhlingsdorf has been managing the business of the up-and-coming medtech scale-up. The main goal for this financial year is to lead the company from the start-up into the growth phase. The CEO's expertise and numerous years of industry know-how will be decisive in this process.

Munich, Germany, January 13^th, 2020 – German med-tech company Mecuris GmbH has successfully concluded a new funding round amounting to 3.6 million euros. In addition to the seed investors Bayern Kapital and High-Tech Gründerfonds (HTGF), the international investment company Mulcan, life science venture capital investor Vesalius Biocapital, and Sana Kliniken AG, one of the top five hospital chains in Germany, are once again also on board.

München, 13.12.2019 – Die Bundesregierung sieht großes Potenzial im Einsatz von 3D-Druck in der Medizintechnik – insbesondere für patientenindividuelle Sonderanfertigungen von Prothesen oder Orthesen. Das geht aus der Antwort auf die kleine Anfrage der FDP-Bundestagsfraktion „Prothesen aus dem 3D-Drucker für Menschen mit Behinderungen" hervor.

Turku, Finland, December 11^th 2019: Forendo Pharma, a clinical stage drug development company focusing on novel treatments in women's health, today announces signing of a License and Collaboration Agreement with Novartis. The joint research collaboration is aimed at the identification of novel drugs for the treatment of chronic liver diseases. Novartis receives a worldwide exclusive license to drug candidates generated under the collaboration.

August 27^th 2019: Tonic App, the startup that developed the favourite mobile application of more than 12,000 medical doctors, has raised 3.5 million euros in a round co-led by Vesalius Biocapital Partners (Luxembourg) and Armilar Venture Partners (Portugal), joining Portugal Ventures and TheVentureCity.

Mecuris GmbH, a commercial-stage Munich-based medical technology startup focusing on the digitalization of prosthetics and orthotics, has been listed as one of the Best European MedTech Startups by Valuer. Vesalius Biocapital supports the innovative Mecuris approach since January 2019.

Turku, Finland, August 20^th 2019: Forendo Pharma, a clinical stage drug development company focusing on novel treatments in women's health, today announces initiation of dosing in a Phase 1b clinical study in its lead endometriosis program with the aim to demonstrate Proof of Mechanism.